CN100475208C - 高脂血症治疗药剂 - Google Patents

高脂血症治疗药剂 Download PDF

Info

Publication number
CN100475208C
CN100475208C CNB2005800053563A CN200580005356A CN100475208C CN 100475208 C CN100475208 C CN 100475208C CN B2005800053563 A CNB2005800053563 A CN B2005800053563A CN 200580005356 A CN200580005356 A CN 200580005356A CN 100475208 C CN100475208 C CN 100475208C
Authority
CN
China
Prior art keywords
eicosapentaenoic acid
hyperlipidemia
pitavastatin
present
triglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005800053563A
Other languages
English (en)
Chinese (zh)
Other versions
CN1921860A (zh
Inventor
青木太郎
山口纯司
佐佐木裕辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Publication of CN1921860A publication Critical patent/CN1921860A/zh
Application granted granted Critical
Publication of CN100475208C publication Critical patent/CN100475208C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
CNB2005800053563A 2004-02-19 2005-02-18 高脂血症治疗药剂 Expired - Fee Related CN100475208C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/780,640 2004-02-19
US10/780,640 US7022713B2 (en) 2004-02-19 2004-02-19 Hyperlipemia therapeutic agent

Publications (2)

Publication Number Publication Date
CN1921860A CN1921860A (zh) 2007-02-28
CN100475208C true CN100475208C (zh) 2009-04-08

Family

ID=34860884

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005800053563A Expired - Fee Related CN100475208C (zh) 2004-02-19 2005-02-18 高脂血症治疗药剂

Country Status (14)

Country Link
US (2) US7022713B2 (https=)
EP (1) EP1715865B9 (https=)
JP (1) JP5474276B2 (https=)
KR (1) KR101376449B1 (https=)
CN (1) CN100475208C (https=)
AT (1) ATE460164T1 (https=)
CY (1) CY1110133T1 (https=)
DE (1) DE602005019856D1 (https=)
DK (1) DK1715865T3 (https=)
ES (1) ES2342609T3 (https=)
PL (1) PL1715865T3 (https=)
PT (1) PT1715865E (https=)
SI (1) SI1715865T1 (https=)
WO (1) WO2005079797A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
JP5069448B2 (ja) * 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
EP2526937A1 (en) * 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US7728697B2 (en) * 2006-09-26 2010-06-01 Mg Materials Corporation Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
EP2308493A4 (en) * 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SI2395991T1 (sl) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2488022B1 (en) * 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) * 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2926335C (en) 2013-10-30 2021-11-23 Banner Life Sciences Llc Enteric soft capsules comprising polyunsaturated fatty acids
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2016026139A1 (zh) * 2014-08-22 2016-02-25 财团法人国防教育研究基金会 用于治疗非酒精性脂肪肝疾病的药物及应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370544A (zh) * 2001-02-27 2002-09-25 张洪超 一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法
CN1410075A (zh) * 2001-09-30 2003-04-16 中国药品生物制品检定所 海狗油作为制备治疗脂代谢紊乱（高血脂）药的应用
CN1543468A (zh) * 2001-08-16 2004-11-03 ������ҩ��ҵ���޹�˾ 制备他汀类的钙盐形式的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
ATE236627T1 (de) * 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1534243A4 (en) * 2002-08-26 2008-08-13 Lipid Sciences Inc TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370544A (zh) * 2001-02-27 2002-09-25 张洪超 一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法
CN1543468A (zh) * 2001-08-16 2004-11-03 ������ҩ��ҵ���޹�˾ 制备他汀类的钙盐形式的方法
CN1410075A (zh) * 2001-09-30 2003-04-16 中国药品生物制品检定所 海狗油作为制备治疗脂代谢紊乱（高血脂）药的应用

Also Published As

Publication number Publication date
US20060111437A1 (en) 2006-05-25
EP1715865B9 (en) 2010-12-15
DE602005019856D1 (de) 2010-04-22
EP1715865B1 (en) 2010-03-10
KR20060109988A (ko) 2006-10-23
HK1098953A1 (zh) 2007-08-03
JP2007523049A (ja) 2007-08-16
JP5474276B2 (ja) 2014-04-16
WO2005079797A3 (en) 2006-05-11
EP1715865A2 (en) 2006-11-02
PT1715865E (pt) 2010-04-01
DK1715865T3 (da) 2010-05-10
US7022713B2 (en) 2006-04-04
WO2005079797A2 (en) 2005-09-01
SI1715865T1 (sl) 2010-08-31
CN1921860A (zh) 2007-02-28
EP1715865B8 (en) 2010-05-19
US7776881B2 (en) 2010-08-17
KR101376449B1 (ko) 2014-03-19
ES2342609T3 (es) 2010-07-09
PL1715865T3 (pl) 2010-09-30
US20050187292A1 (en) 2005-08-25
ATE460164T1 (de) 2010-03-15
CY1110133T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
CN100475208C (zh) 高脂血症治疗药剂
EP2007429B1 (en) Oral formulation with beneficial cardiovascular effects, comprising berberine
KR101840082B1 (ko) 지질 대사 장애의 치료에 유용한 조성물
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
KR20070047766A (ko) 고지혈증 치료제
US20040014712A1 (en) Blood lipid ameliorant composition
JP2016525564A (ja) 親油性スタチンと組合せ使用したメトトレキサートの効果向上
US6916849B2 (en) Compositions for improving lipid content in the blood
WO2016074957A9 (en) Combination
US20040023919A1 (en) Blood lipid ameliorant composition
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
HK1098953B (en) Hyperlipemia therapeutic agent
WO2004096276A9 (ja) 糖取り込み能増強剤
CA2494916A1 (en) Medicinal composition for lowering blood lipid level
US20080247962A1 (en) Pharmaceutical Compositions Comprising Higher Primary Aliphatic Alcohols and Hmg Coa Reductase Inhibitor and Process of Preparation Thereof
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
JP2005089300A (ja) 高脂血症治療剤
CA2494801A1 (en) Medicinal composition containing hmg-coa reductase inhibitor
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
HK1132908A (en) Drug formulation containing fibrate medicament and process for producing the same
WO2018092085A1 (ru) Фармацевтическая композиция для лечения туберкулеза
JP2007008923A (ja) フィブラート系薬剤を含有する製剤及びその製造方法
KR20090035643A (ko) 피브레이트계 약제를 함유하는 제제 및 그의 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098953

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098953

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090408

Termination date: 20190218

CF01 Termination of patent right due to non-payment of annual fee